AP3287A - Hydrate of 1-{(2S)-2-amino-4-[2,4-bis(trifluoromethyl)-5,8-DI-hydropyrido[3,4-D]pyrimidin-7(6H)-YL]-4-oxobutyl}-5,5-difluoro-piperidin-2-one tartrate - Google Patents

Hydrate of 1-{(2S)-2-amino-4-[2,4-bis(trifluoromethyl)-5,8-DI-hydropyrido[3,4-D]pyrimidin-7(6H)-YL]-4-oxobutyl}-5,5-difluoro-piperidin-2-one tartrate

Info

Publication number
AP3287A
AP3287A AP2013006866A AP2013006866A AP3287A AP 3287 A AP3287 A AP 3287A AP 2013006866 A AP2013006866 A AP 2013006866A AP 2013006866 A AP2013006866 A AP 2013006866A AP 3287 A AP3287 A AP 3287A
Authority
AP
ARIPO
Prior art keywords
hydropyrido
oxobutyl
pyrimidin
piperidin
difluoro
Prior art date
Application number
AP2013006866A
Other languages
English (en)
Other versions
AP2013006866A0 (en
Inventor
Ki-Sook Park
Jung Min Yun
Bong Chan Kim
Original Assignee
Lg Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45995015&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP3287(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lg Life Sciences Ltd filed Critical Lg Life Sciences Ltd
Publication of AP2013006866A0 publication Critical patent/AP2013006866A0/xx
Application granted granted Critical
Publication of AP3287A publication Critical patent/AP3287A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
AP2013006866A 2010-11-01 2011-10-31 Hydrate of 1-{(2S)-2-amino-4-[2,4-bis(trifluoromethyl)-5,8-DI-hydropyrido[3,4-D]pyrimidin-7(6H)-YL]-4-oxobutyl}-5,5-difluoro-piperidin-2-one tartrate AP3287A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20100107868 2010-11-01
PCT/KR2011/008186 WO2012060590A2 (en) 2010-11-01 2011-10-31 Hydrate of 1-{(2s)-2-amino-4-[2,4-bis(trifluoromethyl)-5,8-di- hydropyrido[3,4-d]pyrimidin-7(6h)-yl]-4-oxobutyl}-5,5-difluoro-piperidin-2-one tartrate

Publications (2)

Publication Number Publication Date
AP2013006866A0 AP2013006866A0 (en) 2013-05-31
AP3287A true AP3287A (en) 2015-05-31

Family

ID=45995015

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2013006866A AP3287A (en) 2010-11-01 2011-10-31 Hydrate of 1-{(2S)-2-amino-4-[2,4-bis(trifluoromethyl)-5,8-DI-hydropyrido[3,4-D]pyrimidin-7(6H)-YL]-4-oxobutyl}-5,5-difluoro-piperidin-2-one tartrate

Country Status (29)

Country Link
US (1) US8859567B2 (es)
EP (1) EP2635580B1 (es)
JP (1) JP6193762B2 (es)
KR (1) KR101446789B1 (es)
CN (1) CN103189375B (es)
AP (1) AP3287A (es)
AR (1) AR083591A1 (es)
AU (1) AU2011324253B2 (es)
BR (1) BR112013010586A2 (es)
CA (1) CA2814357C (es)
CL (1) CL2013001137A1 (es)
CO (1) CO6710945A2 (es)
DO (1) DOP2013000090A (es)
EA (1) EA024679B1 (es)
EC (1) ECSP13012599A (es)
GE (1) GEP20156218B (es)
IL (1) IL225808A (es)
MA (1) MA34625B1 (es)
MX (1) MX341584B (es)
MY (1) MY156428A (es)
NZ (1) NZ609644A (es)
PE (3) PE20240220A1 (es)
PH (1) PH12013500685A1 (es)
SG (1) SG189931A1 (es)
TW (1) TWI519533B (es)
UA (1) UA106445C2 (es)
UY (1) UY33696A (es)
WO (1) WO2012060590A2 (es)
ZA (1) ZA201302646B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2007752B1 (en) 2006-03-31 2010-08-18 Janssen Pharmaceutica NV Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine h4 receptor
US9371311B2 (en) 2008-06-30 2016-06-21 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine derivatives
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
MX373874B (es) 2013-03-06 2020-03-26 Janssen Pharmaceutica Nv Moduladores benzoimidazol-2-il pirimidinas del receptor h4 de histamina.
MX2023004218A (es) * 2020-10-13 2023-04-21 Lg Chemical Ltd Formulacion combinada oral que incluye gemigliptina y dapagliflozina y metodo de preparacion para la misma.
KR20250137744A (ko) 2024-03-11 2025-09-19 엠에프씨 주식회사 제미글립틴의 신규 결정형 및 이의 제조방법
KR20250147756A (ko) 2024-03-27 2025-10-14 엠에프씨 주식회사 신규한 형태의 제미글립틴 말산염 결정형 및 이의 제조방법
KR20250155700A (ko) 2024-04-24 2025-10-31 주식회사 다산제약 제미글립틴 산부가염 제조방법 및 이를 유효성분으로 포함하는 dpp-4 저해용 조성물
KR20260014098A (ko) 2024-07-23 2026-01-30 동방에프티엘(주) 피리도[3,4-d]피리미딘 치환된 피페리딘-2-온 유도체의 안정한 염 형태 및 이의 제조방법
CN119285630B (zh) * 2024-09-05 2025-05-27 安徽峆一药业股份有限公司 一种吉格列汀草酸盐及其晶型、制备方法与应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060040963A1 (en) * 2002-07-15 2006-02-23 Mathvink Robert J Piperidino pyrimidine dipeptidyl peptidase inhibitors for the treatment of diabetes
US20060074087A1 (en) * 2003-01-31 2006-04-06 Ashton Wallace T 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
KR100776623B1 (ko) * 2005-04-01 2007-11-15 주식회사 엘지생명과학 디펩티딜 펩티데이즈-ⅳ(ｄｐｐ-ⅳ) 저해용 신규 화합물,그것의 제조방법 및 그것을 활성성분으로서 함유하는 약제조성물

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060040963A1 (en) * 2002-07-15 2006-02-23 Mathvink Robert J Piperidino pyrimidine dipeptidyl peptidase inhibitors for the treatment of diabetes
US20060074087A1 (en) * 2003-01-31 2006-04-06 Ashton Wallace T 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
KR100776623B1 (ko) * 2005-04-01 2007-11-15 주식회사 엘지생명과학 디펩티딜 펩티데이즈-ⅳ(ｄｐｐ-ⅳ) 저해용 신규 화합물,그것의 제조방법 및 그것을 활성성분으로서 함유하는 약제조성물

Also Published As

Publication number Publication date
WO2012060590A2 (en) 2012-05-10
AP2013006866A0 (en) 2013-05-31
KR101446789B1 (ko) 2014-10-01
MA34625B1 (fr) 2013-10-02
US20130203787A1 (en) 2013-08-08
PH12013500685A1 (en) 2015-10-02
MX2013004776A (es) 2013-11-04
CN103189375B (zh) 2016-08-10
ECSP13012599A (es) 2013-07-31
EP2635580A2 (en) 2013-09-11
CL2013001137A1 (es) 2013-09-06
CN103189375A (zh) 2013-07-03
PE20180464A1 (es) 2018-03-06
ZA201302646B (en) 2014-01-29
CO6710945A2 (es) 2013-07-15
BR112013010586A2 (pt) 2016-08-09
AR083591A1 (es) 2013-03-06
CA2814357A1 (en) 2012-05-10
MX341584B (es) 2016-08-25
EA024679B1 (ru) 2016-10-31
US8859567B2 (en) 2014-10-14
GEP20156218B (en) 2015-01-12
TWI519533B (zh) 2016-02-01
NZ609644A (en) 2016-02-26
JP2013540810A (ja) 2013-11-07
WO2012060590A3 (en) 2012-06-28
PE20240220A1 (es) 2024-02-16
MY156428A (en) 2016-02-26
AU2011324253A1 (en) 2013-05-02
UA106445C2 (ru) 2014-08-26
IL225808A0 (en) 2013-06-27
SG189931A1 (en) 2013-06-28
TW201245189A (en) 2012-11-16
UY33696A (es) 2012-04-30
DOP2013000090A (es) 2018-06-30
AU2011324253B2 (en) 2015-10-29
CA2814357C (en) 2015-07-07
EP2635580B1 (en) 2015-08-12
EP2635580A4 (en) 2014-04-02
IL225808A (en) 2016-08-31
EA201390644A1 (ru) 2014-11-28
KR20120046069A (ko) 2012-05-09
JP6193762B2 (ja) 2017-09-06
PE20140392A1 (es) 2014-03-22

Similar Documents

Publication Publication Date Title
AP3287A (en) Hydrate of 1-{(2S)-2-amino-4-[2,4-bis(trifluoromethyl)-5,8-DI-hydropyrido[3,4-D]pyrimidin-7(6H)-YL]-4-oxobutyl}-5,5-difluoro-piperidin-2-one tartrate
AP3751A (en) Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines
AP3709A (en) Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
PL2536722T3 (pl) Związki bicykliczne i ich zastosowanie jako podwójne inhibitory c-src / jak
PH12013501402A1 (en) Mesoionic Pyrido [1,2 -A] Pyrimidine Pesticides
IL227526A0 (en) Derivatives of 6-cyclobutyl-1,5-dihydro-pyrazolo [3,4-d] pyrimidine-4-one and their use as a9pde inhibitors
IL229993A (en) 8 - Alkoxy [1,2,4] triazolo [5,1 – c] pyrimidine– 2
ZA201208616B (en) Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations
IL222836A0 (en) Biologic female contraceptives
IL220448A (en) Pyridine [3,2 - d] Pyrimidine - 7 (8h) - Their medical uses and uses
EP2490693A4 (en) Pyrazolo [3,4-B] PYRIDINE-4-ON-KINASE INHIBITORS
ZA201303580B (en) Oxazolo [5,4-b]pyridin-5-yl compounds and their use for the treatment of cancer
TN2013000161A1 (en) Hydrate of 1-{(2s)-2-amino-4-[2,4-bis(trifluoromethyl)-5,8-di- hydropyrido[3,4-d]pyrimidin-7(6h)-yl]-4-oxobutyl}-5,5-difluoro-piperidin-2-one tartrate
ZA201206945B (en) Bicyclic compounds and their uses as dual c-src/jak inhibitors
HK1176060A (en) Imidazo[1,2-b][1,2,4]triazines as c-met inhibitors
HK1166631A (en) Isoxazol-3(2h)-one analogs as therapeutic agents